NSCLC

[Cell Death & Disease] Scientists found that exosomal lncRNA-SOX2OT derived from non-small cell lung cancer cells promoted cell invasion and migration in vitro, as well as bone metastasis in vivo.

[Bristol Myers Squibb] Bristol Myers Squibb announced that the European Commission has approved Opdivo plus Yervoy for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.

[Nature Communications] Researchers complemented PD-L1 immunohistochemistry and tumor mutation burden with RNA-seq in 366 patients to identify unifying and indication-specific molecular profiles that could predict response to checkpoint blockade across tumor types.

[Oncogene] Researchers found that loss of lung cell lineage and gain of stem cell-like characteristics, along with mutator and immune evasion phenotypes, explained the aggressive behavior of a specific subset of lung adenocarcinoma (LUAD) that was called C1-LUAD, including early-stage disease.

[Communications Biology] Investigators showed that TGF-β induced reprogramming of intracellular amino acid metabolism, which was necessary to promote epithelial–mesenchymal transition in non-small cell lung cancer cells.

[Nature Reviews Clinical Oncology] The authors discuss the current treatment landscape and detail their approach to first-line immunotherapy regimen selection for patients with advanced-stage, driver-negative NSCLC.